Background: Rituximab as a combination of chemotherapy (R-CHOP) is more effective in the treatment of Lymphoma Non-Hodgkini (NHL). Production of humoral immune response frequently decreases the efficacy of antibody therapy due to premature clearance of antibodies, thus limiting the effectiveness of anti-tumor responses. We determined the correlation between anti-rituximab antibody levels and the response of RCHOP-treated NHL patients who receiving. Methods: This study was an observational analytic cross-sectional study on NHL patients in the Division of Hematology of Medical Oncology at Dr.Soetomo General Hospital Surabaya. Anti rituximab antibody titer was measured by ELISA from serum samples and the treatment response was evaluated according to category of response criteria for clinical trial (complete response, partial response, stable disease or progressive disease). Results: This study was enrolled 54 subjects that consisted of 64.8% of male, mean age of patients was 49.167 ± 12,075 years old, stage III was highest (61.6%). Median anti-rituximab antibody titer of 21.55 (9.24-197.17) pg/mL. The most progressive disease therapeutic response group was 46.3%. Comparative analysis of anti-rituximab antibody titer in each treatment response group was not significant (p-value = 0.08). The results of the correlation test are significant (p-value = 0.04; r Spearman =-0.27). Conclusion: There was weak negative correlation between anti-rituximab antibody titer and therapeutic response in R-CHOP-treated NHL patients.
|Number of pages||6|
|Journal||New Armenian Medical Journal|
|Publication status||Published - 2019|
- Anti rituximab antibody
- Non-hodgkin’s lymphoma
- Therapeutic response